Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential XELIRI + bevacizumab versus XELOX + bevacizumab in metastatic colorectal cancer
2011-002191-16Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, irinotecan, bevacizumab, oxaliplatin in colorectal cancer (CRC), sponsored by Medical University of Vienna. Started Jun 2011; status: completed.
02
Drugs
capecitabineirinotecanbevacizumaboxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-002191-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002191-16.